PULSE BIOSCIENCES, INC. (PLSE) - Dilution Analysis

10-Q filing | 68.0M shares outstanding

10-Q filing | 67.4M shares outstanding

8-K filing: The Company's stockholders ratified the grant of options to certain Company directors to purchase up to 600,000 shares of Company common stock.

10-Q filing | 67.3M shares outstanding

10-Q filing | 67.1M shares outstanding

10-K filing | 65.9M shares outstanding

10-Q filing | 61.1M shares outstanding

10-Q filing | 57.2M shares outstanding

POS AM filing: Pulse Biosciences, Inc. is distributing at no charge to the holders of their common stock, non-transferable subscription rights to purchase up to 6,000,000 Units at the Initial Price with an aggregate offering value of up to $60,000,000.

10-Q filing | 55.2M shares outstanding

8-K filing: Pulse Biosciences, Inc. announced the record date for its previously announced rights offering, which will be available to stockholders of record as of May 16, 2024, to purchase up to 6,000,000 units at a price of up to $10 per unit, potentially generating gross proceeds of up to $60,000,000. ($60.0M proceeds)

S-3/A filing: Pulse Biosciences, Inc. is filing an S-3/A to distribute non-transferable subscription rights to purchase up to 6,000,000 Units, each consisting of one share of common stock and two warrants, with an aggregate offering value of up to $60,000,000, to raise equity capital for general corporate purposes.

S-3/A filing: Pulse Biosciences, Inc. is distributing at no charge to the holders of their common stock, non-transferable subscription rights to purchase up to 6,000,000 Units with an aggregate offering value of up to $60,000,000.

S-3/A filing: Pulse Biosciences, Inc. is distributing at no charge to the holders of their common stock, non-transferable subscription rights to purchase up to 6,000,000 Units at the Initial Price with an aggregate offering value of up to $60,000,000.

S-3/A filing: Pulse Biosciences, Inc. is distributing at no charge to the holders of their common stock, non-transferable subscription rights to purchase up to 6,000,000 Units at the Initial Price with an aggregate offering value of up to $60,000,000.

S-3 filing: Pulse Biosciences, Inc. is distributing at no charge to the holders of their common stock, non-transferable subscription rights to purchase up to 6,000,000 Units at the Initial Price with an aggregate offering value of up to $60,000,000.

10-K filing | 55.1M shares outstanding

S-3 filing: Pulse Biosciences files an S-3 to offer common stock, preferred stock, debt securities, depositary shares, subscription rights, purchase contracts, and units up to an aggregate offering price of $50,000,000.

8-K filing: On December 19, 2023, the Company's stockholders ratified the grant of options to purchase up to 1,505,000 shares of Company common stock to certain Company executives, with an exercise price of $4.38 per share.

10-Q filing | 54.9M shares outstanding

S-3 filing: Pulse Biosciences, Inc. is offering up to 10,022,937 shares of common stock by the selling securityholder.

10-Q filing | 54.8M shares outstanding

10-Q filing | 37.4M shares outstanding

8-K filing: Pulse Biosciences consummated a private placement with Robert W. Duggan, where Mr. Duggan purchased 10,022,937 shares of the Company's common stock at a price of $6.51 per share. ($65.25M proceeds)

8-K filing: Pulse Biosciences, Inc. issued 10,022,937 shares of common stock to Robert W. Duggan in a private placement at a price of $6.51 per share, canceling $65 million in debt. ($65.25M proceeds)

10-K filing | 33.9M shares outstanding

10-Q filing | 37.2M shares outstanding

10-Q filing | 37.1M shares outstanding

8-K filing: Pulse Biosciences, Inc. closed a rights offering on June 9, 2022, selling 7,317,072 units at $2.05 per unit, resulting in gross proceeds of $15 million and bringing the total shares outstanding to 37,119,352. ($15.0M proceeds)

8-K filing: Pulse Biosciences expects to issue approximately 7.3 million shares in aggregate at a price of $2.05 per unit, with each unit consisting of one share of Company common stock and a warrant to purchase one share of Company common stock at an exercise price of $2.05. ($15.0M proceeds)

10-Q filing | 29.8M shares outstanding

10-K filing | 29.8M shares outstanding

8-K filing: Pulse Biosciences, Inc. appointed Kevin Danahy as Chief Commercial Officer and issued him options to acquire 300,000 shares of common stock at an exercise price of $6.41 per share.

10-Q filing | 29.6M shares outstanding

S-3 filing: This S-3 filing indicates a shelf registration for the resale of common stock by a selling securityholder.

10-Q filing | 29.6M shares outstanding

8-K filing: Pulse Biosciences, Inc. entered into a Securities Purchase Agreement to issue and sell 3,048,780 shares of common stock to Robert W. Duggan at $16.40 per share, using a combination of debt conversion and cash payment. ($50.0M proceeds)

8-K filing: Pulse Biosciences, Inc. amended the 2017 Inducement Equity Incentive Plan to reserve an additional 1,000,000 shares of the Company's common stock for issuance pursuant to the Inducement Plan.

10-Q filing | 26.5M shares outstanding

10-K filing | 26.1M shares outstanding

8-K filing: Pulse Biosciences, Inc. redeemed 5,139 warrants for $0.01 per warrant and 636,432 warrants were exercised generating approximately $4.5 million of gross proceeds. As of February 9, 2021, the Company had 26,061,975 shares of Common Stock outstanding. ($4.5M proceeds)

10-Q filing | 25.3M shares outstanding

S-3 filing: This is a shelf registration for various types of securities, including common stock, preferred stock, and debt securities, with a total offering price not exceeding $250,000,000.

10-Q filing | 25.2M shares outstanding

10-Q filing | 20.9M shares outstanding

S-3/A filing: This S-3/A filing discusses a rights offering for common stock and warrants, with gross proceeds of approximately $30 million if all rights are exercised, to fund working capital purposes.

S-3/A filing: This S-3/A filing discusses a rights offering where the company is offering units, each consisting of one share of common stock and 0.15 warrants, to raise capital for general working capital purposes and other corporate activities.

S-3/A filing: Pulse Biosciences, Inc. is distributing at no charge to the holders of their common stock, non-transferable subscription rights to purchase up to $30,000,000 of Units, each unit consisting of one share of common stock and 0.15 warrants to purchase shares of common stock, to raise equity capital for general working capital purposes.

S-3/A filing: This is an S-3/A filing to correct Exhibit 23.2 of a previous registration statement (333-237577) to include the conformed signature of Deloitte and Touche LLP and to update the Exhibit List accordingly. This Amendment No. 2 does not modify the prospectus that forms a part of the Registration Statement.

S-3/A filing: Pulse Biosciences, Inc. is offering up to $30,000,000 of shares of common stock to existing stockholders through a rights offering.

S-3 filing: Pulse Biosciences, Inc. is offering up to $30,000,000 of shares of its common stock via a rights offering to existing shareholders.

10-K filing | 20.8M shares outstanding